Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer

被引：0
|
作者：
Rodney, Simon
Stewart, Adam R.
Perez, Victoria Sanchez
Morton, Cienne
Pickard, Lisa A.
Shakouri, Taleen
Prout, Toby
Parmar, Mona
Turner, Alison J.
Coma, Silvia
Pachter, Jonathan
Finneran, Laura
Hall, Emma
Spicer, James
Minchom, Anna
Banerji, Udai
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3461
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3461
引用
收藏
页数：3
相关论文
共 50 条
  • [31] MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer
    Fanini, Francesca
    Bandini, Erika
    Plousiou, Meropi
    Carloni, Silvia
    Wise, Petra
    Neviani, Paolo
    Murtadha, Mariam
    Foca, Flavia
    Fabbri, Francesco
    Vannini, Ivan
    Fabbri, Muller
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (24)
  • [32] GTPase KRAS (G12C mutant) inhibitor Treatment of non-small cell lung cancer Treatment of colorectal cancer
    Shao, Shi-yun
    Rong, Wen-qing
    Talukder, Salehikram
    Jia, Ru
    Chen, Zhe-Sheng
    DRUGS OF THE FUTURE, 2022, 47 (11) : 783 - 795
  • [33] A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC)
    Theriau, Christopher F.
    Feng, Jamie
    Eng, Lawson
    Shepherd, Frances A.
    DeCarolis, Mary
    Glenns, Vivian
    Kulkarni, Swati
    VanderMeer, Rachel
    Zurawska-Fortin, Urszula
    Hao, Desiree
    Le, Lisa
    Wozniczka, Isabel
    Al-Kindy, Aida
    Xie, Danny
    Zhang, Tong
    Subramanian, Vasanth
    Stockley, Tracy
    Bradbury, Penelope A.
    Liu, Geoffrey
    Leighl, Natasha B.
    CANCER RESEARCH, 2023, 83 (08)
  • [34] PRECLINICAL AND CLINICAL ACTIVITY OF BMS-690514 IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)
    Sbar, E. I.
    Wong, T.
    Salvati, M.
    Pathak, A.
    Mokliatchouk, O.
    Park, J.
    Harbison, C.
    Soria, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 53 - 53
  • [35] Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development
    Dienstmann, Rodrigo
    Felip, Enriqueta
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (09) : 1223 - 1231
  • [36] Treatment of brain metastases from non-small cell lung cancer: preclinical, clinical, and translational research
    Sampat, Parth J.
    Cortese, Alyssa
    Goodman, Alexandra
    Ghelani, Ghanshyam H.
    Mix, Michael D.
    Graziano, Stephen
    Basnet, Alina
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [37] Evaluation of the radiosensitizing effect of MEK inhibitor KZ-001 on non-small cell lung cancer cells in vitro
    Huang, Gongchao
    Zhang, Wenqin
    Tian, Hongqi
    ASIAN BIOMEDICINE, 2023, 17 (05) : 230 - 237
  • [38] Photonanozyme-Kras-ribosome combination treatment of non-small cell lung cancer after COVID-19
    Si, Qiaoyan
    Bai, Mingjian
    Wang, Xiaolong
    Wang, Tianyu
    Qin, Yan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [39] Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer
    Mu Yuxin
    Yang Ke
    Hao Xuezhi
    Wang Yan
    Wang Lin
    Liu Yutao
    Lin Lin
    Li Junling
    Xing Puyuan
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [40] Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study
    Khuri, F. R.
    Owonikoko, T. K.
    Subramanian, J.
    Sica, G.
    Behera, M.
    Saba, N. F.
    Chen, Z.
    Tighiouart, M.
    Shin, D. M.
    Sun, S.
    Fu, R.
    Gal, A.
    Govindan, R.
    Ramalingam, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345